Unaudited financial results for the quarter and half year ended 30.09.2025

Revenue declinedNet loss reportedNegative operating cash flowResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.4%Reaction day

₹60.98

prior close

₹62.00

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.9%+1.5% vs market

Healthcare Services peers, median of 49sector · industry level+0.9%+1.6% vs sector

On the reaction day the stock moved 1.5 pts more than Nifty Microcap 250 and 1.6 pts more than its Healthcare Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.8

10m

-1.9

15m

+0.6

30m

+0.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.4+0.9+1.5+0.9+1.6

Next day

+2.3+0.8+1.5+0.7+1.6

+3.2+0.7+2.4+0.8+2.4

+0.2+1.3-1.1+0.9-0.7

+1.7+0.5+1.1-1.1+2.8

+2.9+0.4+2.5-0.1+3.0

+1.2-1.5+2.7-0.3+1.4

15d

+2.5-2.4+4.9-3.1+5.6

+1.7-4.4+6.1-2.8+4.5

+12.1-7.2+19.3-5.7+17.8

+12.5-5.0+17.5-8.6+21.1

UpDownMarket · Nifty Microcap 250Sector · Healthcare Services peers, median of 49Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Jeevan Scientific Technology reported weak H1 FY26 results, with consolidated revenue falling to ₹2,117.86 lakhs from ₹2,427.85 lakhs a year earlier (a decline of roughly 12.8%), while standalone revenue dropped about 18.3% to ₹1,864.74 lakhs. The company swung to a consolidated loss after tax of ₹320.94 lakhs in H1 FY26 versus a profit of ₹127.59 lakhs in H1 FY25, and posted a standalone PAT loss of ₹224.54 lakhs against a prior-year profit of ₹175.07 lakhs. Consolidated net cash from operations turned sharply negative at ₹(194.44) lakhs, and on a standalone basis current borrowings jumped from ₹222.48 lakhs to ₹879.57 lakhs while current tax liabilities also rose meaningfully. Statutory auditor Pavuluri & Co. issued an unmodified review conclusion on both the standalone and consolidated results.

Likely market impact

The swing from profit to loss, declining revenue and negative consolidated operating cash flow point to continued stress in the clinical research business and could weigh on the stock. The sharp build-up in short-term borrowings and current tax liabilities also deserves close monitoring by shareholders.